Further, our results suggest that Gfi1 may contribute to Btz resistance and that targeting Gfi1 may be a novel therapeutic strategy for MM patients, even those harboring p53 mutations or deletions. This evidence concerns the gene GFI1 and Miyoshi myopathy.